High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo
These findings underscore the importance of engineering next-generation anti-IgE therapies with higher affinity and disruptive potency to optimize current treatment approaches.
Authors
- Robin van Brummelen (ORCID: https://orcid.org/0000-0003-1182-8519)
- Luke F. Pennington (ORCID: https://orcid.org/0000-0002-7947-8714)
- Alexander Eggel (ORCID: https://orcid.org/0000-0001-8746-3339)
- Pascal Guntern (ORCID: https://orcid.org/0000-0001-8840-8577)
- Daniel Brigger
- Theodore S. Jardetzky (ORCID: https://orcid.org/0000-0002-3664-0072)
Institutions
- University of Bern (CH)
- University Hospital of Bern (CH)
- Excell Research (United States) (US)
- Stanford University (US)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1016/j.jaci.2025.05.028
- Citations
- 2
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 3.34